Loading clinical trials...

Barriers to Screening Breast MRI Utilization Among Patients at Elevated Risk | Clinical Trials | Clareo Health

COMPLETED

Barriers to Screening Breast MRI Utilization Among Patients at Elevated Risk

Barriers to Screening Breast MRI Utilization Among Patients at Elevated Risk (B-SUPER)

NCT04257474•H. Lee Moffitt Cancer Center and Research Institute

Summary

This study seeks to develop an explanatory framework for breast MRI utilization to inform future interventions. The Health Services Utilization Model (HSUM) will guide the selection of specific participant-level factors for examination, including predisposing characteristics (knowledge, health/cultural beliefs), enabling resources (social support, cost/insurance coverage), and perceived need (perceived susceptibility, provider recommendation).

Eligibility

Age

25 - 85 years

Sex

FEMALE

Healthy Volunteers

Inclusion Criteria

•Ability to speak/read English
•Within 2 years of last screening mammogram
•Pathogenic BRCA1/2 mutations OR estimated lifetime risk ≥20% per the National Cancer Institute (NCI) Breast Cancer Risk Assessment Tool (BCRAT)

Exclusion Criteria

•Women who have received a prior diagnosis of breast cancer

Locations (2)

Georgetown Lombardi Comprehensive Cancer Center

Washington D.C., District of Columbia, United States

Moffitt Cancer Center

Tampa, Florida, United States

Key Dates

Start Date

January 30, 2020

Primary Completion Date

January 19, 2022

Completion Date

January 19, 2022

Last Updated

March 18, 2024

Enrollment

265

ACTUAL participants

Conditions

Breast Cancer

Interventions

Self-Report Survey

BEHAVIORAL

Qualitative Interviews

BEHAVIORAL

Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial

NCT04704661

Advanced Breast CarcinomaAdvanced Colon Carcinoma+38 more

View study

RECRUITINGPHASE1

Testing the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast Cancer

NCT05673200

Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8+2 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 18, 2024Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Barriers to Screening Breast MRI Utilization Among Patients at Elevated Risk

Inclusion Criteria

Exclusion Criteria

Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial

Testing the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast Cancer

Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors

Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations

Safety and Feasibility of Robotic SP Nipple Sparing Mastectomy

A Study of the Impact of Endocrine Therapy on Surgical Outcomes in People With Breast Cancer